Sequencing antiretroviral drugs for long-lasting suppression of HIV replication

New Microbiologica

Volumn 28, Issue 4, 2005, Pages 281-297

  Gianotti, Nicola ^a,b   Lazzarin, Adriano ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Antiretroviral sequencing; Drug resistance; HAART; HIV 1; Mitochondrial toxicity

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; GENETIC SELECTION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; REVIEW; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; SELECTION (GENETICS); VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 29244451381     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. ARION, D., KAUSHIK, N., MCCORMICK, S., BORKOW, G., AND M. A. PARNIAK. (1998). Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry, 37, 15908-15917.
2. ARRIBAS, J., POZNIAK A., GALLANT, J., DEJESUS, E., R. CAMPO, B. GAZZARD, M. HITCHCOCK, B. LU, D. MCCOLL, J. ENEJOSA, A. CHENG, AND FOR THE STUDY 934 TEAM. (2005). Superior outcome for tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naïve patients. In Programme and Abstracts of the 18th International Conference on Antiviral Research, Barcellona, Spain, 10-14 April. Abstract LB-01.
3. BACK, N.K., NIJHUIS, M., KEULEN, W., BOUCHER, C.A., OUDE ESSINK, B.O., VAN KUILENBURG, A.B., VAN GENNIP, A.H., AND BERKHOUT, B. (1996). Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J, 15, 4040-4049.
4. BIRKUS, G., HITCHCOCK, M.J., AND CIHLAR. T. (2002). Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother, 46, 716-723.
5. BOCKET, L., YAZDANPANAH, Y., AJANA, F., GERARD, Y., VIGET, N., GOFFARD, A., ALCARAZ, P. WATTRE, P., AND MOUTON, Y. (2003). Thymidine analogue mutations emergence in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine. In Programme and Abstracts of the XII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Los Cabos, Mexico, June 10-14. Abstract 138.
6. BOZZETTE, S.A., AKE, C.F., TAM, H.K., CHANG S.W., AND LOUIS, T.A. (2003). Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med, 348, 702-710.
7. BRAMBILLA, A.M., NOVATI, R., CALORI, G., MENEGHINI, E., VACCHINI, D., LUZI, L., CASTAGNA, A. AND LAZZARIN, A. (2003). Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS, 17, 1993-1995.
8. BROWN, T.T., LI, X., COLE, S.R., KINGSLEY, L.A., PALELLA F.J., RIDDLER, S.A., CHMIEL, J.S., VISSCHER, B.R., MARGOLICK, J.B. AND DOBS, A.S. (2005). Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS, 19, 1375-1383.
9. CAMPBELL, T.B., SHULMAN, N.S., JOHNSON, S.C., ZOLOPA, A.R., YOUNG R.Y., BUSHMAN, L., FLETCHER, C.V., LANIER, E.R., MERIGAN, T.C., AND KURITZKES, D.R. (2005). Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin. Infect. Dis., 41, 236-242.
10. CASTAGNA, A., GIANOTTI, N., GALLI, L., DANISE, A., HASSON, H., BOERI, E., HOETELMANS, R., NAUWELAERS, D., AND LAZZARIN, A. (2004). The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen. Antivir Ther, 9, 537-543.
11. CLAVEL, F. AND HANCE A.J. (2004). HIV drug resistance. N. Engl. J. Med., 350, 1023-1035.
12. CLOTET, B., RAFFI, F., COOPER, D., DELFRAISSY, J.F., LAZZARIN, A., MOYLE, G., ROCKSTROH, J., SORIANO, V., AND SCHAPIRO, J. (2004). Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 18, 1137-1146.
13. COLONNO, R., ROSE, R., MCLAREN, C., THIRY, A., PARKIN, N., AND FRIBORG, J. (2004). Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect. Dis., 189, 1802-1810.
14. D'ARMINIO MONFORTE, A., LEPRI, A.C., REZZA, G., PEZZOTTI, P., ANTINORI, A., PHILLIPS, A.N., ANGARANO, G., COLANGELI, V., DE LUCA, A., IPPOLITO, G., CAGGESE, L., SOSCIA, F., FILICE, G., GRITTI, F., NARCISO, P., TIRELLI, U., AND MORONI, M. (2000). Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS, 14, 499-507.
15. DEEKS, S.G., HELLMANN, N.S., GRANT, R.M., PARKIN, N.T., PETROPOULOS, C.J., BECKER, M., SYMONDS, W., CHESNEY, M., AND VOLBERDING, P.A. (1999). Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J. Infect. Dis., 179, 1375-1381.
16. DEEKS, S.G. (2001). International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr., 26, Suppl 1, S25-33.
17. DEJESUS, E., GRINSZTEJN, B., RODRIGUEZ, C., NIETO-CISNEROS, L., COCO, J., LAZZARIN, A., LICHTENSTEIN, K., JOHNSON, M., RIGHTMIRE, A., SANKOH, S., AND WILBER, R. (2004). Efficacy and Safety of Atazanavir with Ritonavir or Saquinavir vs Lopinavir/Ritonavir in Patients Who Have Experienced Virologic Failure on Multiple HAART Regimens: 48-Week Results from BMS A1424-045. In Programme and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11. Abstract 547.
18. DEMETER, L., DEGRUTTOLA V., LUSTGARTEN, S., ESHLEMAN, S., HAMMER, S., FISCHL, M., AND SQUIRES, K. (2004). A Genotypic Score for Efavirenz Hypersusceptibility Is Associated with Virologic Response to EFV + Indinavir +/- Abacavir in Nucleoside-experienced Patients. In Progamme and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11. Abstract 669.
19. DESCAMPS, D., FLANDRE, P., CALVEZ, V., PEYTAVIN, G., MEIFFREDY, V., COLLIN, G., DELAUGERRE, C., ROBERT-DELMAS, S., BAZIN, B., ABOULKER, J.P., PIALOUX, G., RAFFI, F., AND BRUN-VEZINET, F. (2000). Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team). JAMA, 283, 205-211.
20. DURAN, S., SAVES, M., SPIRE, B., CAILLETON, V., SOBEL, A., CARRIERI, P., SALMON, D. MOATTI, J.P., LEPORT, C., AND APROCO STUDY GROUP. (2001). Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 15, 2441-2444.
21. ERON, J., DA SILVA, B., KING, M., GULICK, R., BENSON, C., WHITE, A., GLESBY, M., THOMPSON, M., ALBRECHT, M., WOLFE, P., MURPHY, R., HICKS, C., KESSLER, H., AND BRUN, S. (2003). Lopinavir/ritonavir in antiretroviral-naive HIV-infected patients: 5-year follow-up. In Programme and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14-17. Abstract H-844.
22. FENG, J.Y., AND ANDERSON, K.S. (1999). Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry, 38, 9440-9448.
23. FRIIS-MOLLER, N., WEBER, R., REISS, P., THIEBAUT, R., KIRK, O., D'ARMINIO MONFORTE, A., PRADIER, C. MORFELDT, L., MATEU, S., LAW, M., EL-SADR, W., DE WIT, S., SABIN, C.A., PHILLIPS, A.N., LUNDGREN, J.D., AND DAD STUDY GROUP. (2003). Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS, 17, 1179-1193.
24. GALLANT, J., RODRIGUEZ, A., AND WEINBERG, W. (2003). Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. In Programme and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14-17. Abstract H-1722a.
25. GALLANT, J.E., STASZEWSKI, S., POZNIAK, A.L., DEJESUS, E., SULEIMAN, J.M., MILLER, M.D., COAKLEY, D.F., LU, B., TOOLE, J.J., CHENG, A.K., AND 903 STUDY GROUP. (2004). Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA, 292, 191-201.
26. GATHE, J.C., JR, IVE, P., WOOD, R., SCHURMANN, D., BELLOS, N.C., DEJESUS, E., GLADYSZ, A., GARRIS, C., AND YEO, J. (2004a). SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS, 18, 1529-1537.
27. GATHE, J., PODZAMCZERR, D., JOHNSON, M., SCHWARTZ, R., YEH, V., TRAVES, N., LUFF, K., KING, M., TRESSLER, R., AND BRUN, S. (2004b). Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results. In Programme and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11. Abstract 570.
28. GIANOTTI, N., GALLI, L., BOERI, E., DE BONA, A., GUFFANTI, M., DANISE, A., SALPIETRO, S., LAZZARIN, A., AND CASTAGNA, A. (2005). Determinants of Virologie Response to Stavudine in Failing Patients Starting a Stavudine-Including HAART Regimen. In Programme and Abstracts of the 3rd European HIV Drug Resistance Workshop, Athens, Greece, March 30-April 1. Abstract 65.
29. GULICK, R.M., RIBAUDO, H.J., SHIKUMA, C.M., LUSTGARTEN, S., SQUIRES, K.E., W.A. MEYER 3RD, ACOSTA, E.P., SCHACKMAN, B.R., PILCHER, C.D., MURPHY, R.L., MAHER, W.E., WITT, M.D., REICHMAN, R.C., SNYDER, S., KLINGMAN, K.L., KURITZKES, D.R., AND AIDS CLINICAL TRIALS GROUP STUDY A5095 TEAM. (2004). Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med., 350, 1850-1861.
30. HIRSCH, M.S., BRUN-VEZINET, F., CLOTET, B., CONWAY, B., KURITZKES, D.R., D'AQUILA, R.T., DEMETER, L.M., HAMMER, S.M., JOHNSON, V.A., LOVEDAY, C., MELLORS, J.W., JACOBSEN, D.M., AND RICHMAN, D.D. (2003). Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis., 37, 113-128.
31. HOGG, R., BANGSBERG, D., ALEXANDER, C., BONNER, S., YIP, B., WOOD, E., DONG, W., WYNHOVEN, B., MONTANER, J., AND HARRIGAN, P. (2005). Drug resistance is associated with an increased risk of death in patients first starting HAART. In Programme and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25. Abstact 712.
32. IMHOF, A., LEDERGERBER, B., GUNTHARD, H.F., HAUPTS, S., WEBER, R., AND SWISS HIV COHORT STUDY. (2005). Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clin. Infect. Dis., 41, 721-728.
33. JEMSEK, J., HUTCHERSON, P., AND E. HARPER. (2004). Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. In Programme and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11. Abstract 51.
34. JOHNSON, M., GRINSZTEJN, B., RODRIGUEZ, C., COCO, J., DEJESUS, E., LAZZARIN, A., LICHTENSTEIN, K., RIGHTMIRE, A., SANKOH, S., AND WILBER, R. (2005). Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS, 19, 685-694.
35. JOHNSON, V.A., BRUN-VEZINET, F., CLOTET, B., CONWAY, B., KURITZKES, D.R., PILLAY, D., SCHAPIRO, J., TELENTI, A., AND RICHMAN, D. (2005). Update of the Drug Resistance Mutations in HIV-1: 2005. Top. HIV. Med., 13, 51-57.
36. KATZENSTEIN, D.A., BOSCH, R.J., HELLMANN, N., WANG, N., BACHELER, L., ALBRECHT, M.A., AND ACTG 364 STUDY TEAM. (2003). Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS, 17, 821-830.
37. KAVLICK, M.F., WYVILL, K., YARCHOAN, R., AND MITSUYA, H. (1998). Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J. Infect. Dis., 177, 1506-1513.
38. KEMPF, D.J., KING, M.S., BERNSTEIN, B., CERNOHOUS, P., BAUER, E., MOSELEY, J., GU, K., HSU, A., BRUN, S., AND SUN, E. (2004). Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis., 189, 51-60.
39. KURITZKES, D.R., QUINN, J.B., BENOIT, S.L., SHUGARTS, D.L., GRIFFIN, A., BAKHTIARI, M., POTICHA, D., ERON, J.J., FALLON, M.A., AND RUBIN, M. (1996). Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS, 10, 975-981.
40. LALEZARI, J.P., HENRY, K., O'HEARN, M., MONTANER, J.S., PILIERO, P.J., TROTTIER, B., WALMSLEY, S., COHEN, C., KURITZKES, D.R., ERON JR, J.J., CHUNG, J., DEMASI, R., DONATACCI, L., DROBNES, C., DELEHANTY, J., SALGO, M., AND TORO 1 STUDY GROUP. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med., 348, 2175-2185.
41. LANIER, E., IRLBECK, D., ROSS, L., GERONDELIS, P., UNDERWOOD, M., PARKIN, N., CHAPPEY, C., AND ST CLAIR, M. (2003). Prediction of NRTI options by linking reverse transcriptase genotype to phenotypic breakpoints. In Programme and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14. Abstract 586.
42. LANIER, E.R., AIT-KHALED, M., SCOTT, J., STONE, C., MELBY, T., STURGE, G., ST CLAIR, M., STEEL, H., HETHERINGTON, S., PEARCE, G., SPREEN, W., AND LAFON, S. (2004). Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir Ther., 9, 37-45.
43. LAZZARIN, A., CLOTET, B., COOPER, D., REYNES, J., ARASTEH, K., NELSON, M., KATLAMA, C., STELLBRINK, H.J., DELFRAISSY, J.F., LANGE, J., HUSON, L., DEMASI, R., WAT, C., DELEHANTY, J., DROBNES, C., SALGO, M., AND TORO 2 STUDY GROUP. (2003). Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med., 348, 2186-2195.
44. MACMANUS, S., YATES, P.J., ELSTON, R.C., WHITE, S., RICHARDS, N., AND SNOWDEN, W. (2004). GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS, 18, 651-655.
45. MAGGIOLO, F., MIGLIORINO, M., MASERATI, R., PAN, A., RIZZI, M., PROVETTONI, G., RIZZI, L., SUTER, F., AND ONCE STUDY GROUP. (2001). Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther, 6, 249-253.
46. MAGGIOLO, F., CALLEGARO, A., RIPAMONTI, D., NEMIS, S., ACERBIS, A., GOGLIO, A., AND SUTER. F. (2005). in vivo Determination of Stavudine Activity in the Presence of TAM. In Programme and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25. Abstract 706.
47. MALLON, P.W., UNEMORI, P., SEDWELL, R., MOREY, A., RAFFERTY, M., WILLIAMS, K., CHISHOLM, D., SAMARAS, K., EMERY, S., KELLEHER, A., COOPER, D.A., CARR, A., AND SAMA INVESTIGATORS. (2005). In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J. Infect. Dis. 191, 1686-1696.
48. MARCELIN, A.GLAMOTTE, C., DELAUGERRE, C., KTORZA, N., AIT MOHAND, H., CACACE, R., BONMARCHAND, M., WIRDEN, M., SIMON, A., BOSSI, P., BRICAIRE, F., COSTAGLIOLA, D., KATLAMA, C., PEYTAVIN, G., CALVEZ, V., AND GENOPHAR STUDY GROUP. (2003). Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother., 47, 594-600.
49. MARCELIN, A.G., COHEN-CODAR, I., KING, M.S., COLSON, P., GUILLEVIC, E., DESCAMPS, D., LAMOTTE, C., SCHNEIDER, V., RITTER, J., SEGONDY, M., PEIGUE-LAFEUILLE, H., MORAND-JOUBERT, L., SCHMUCK, A., RUFFAULT, A., PALMER, P., CHAIX, M.L., MACKIEWICZ, V., BRODARD, V., IZOPET, J., COTTALORDA, J., KOHLI, E., CHAUVIN, J.P., KEMPF, D.J., PEYTAVIN, G., AND CALVEZ, V. (2005a). Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob. Agents Chemother., 49, 1720-1726.
50. MARCELIN, A.G., FLANDRE, P., PAVIE, J., SCHMIDELY, N., WIRDEN, M., LADA, O., CHICHE, D., MOLINA, J.M., CALVEZ, V., AND AI454-176 JAGUAR STUDY TEAM. (2005b). Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob. Agents Chemother., 49, 1739-1744.
51. MARTINEZ, E., ARNAIZ, J.A., PODZAMCZER, D., DALMAU, D., RIBERA, E., DOMINGO, P., KNOBEL, H., RIERA, M., PEDROL, E., FORCE, L., LLIBRE, J.M., SEGURA, F., RICHART, C., CORTES, C., JAVALOYAS, M., ARANDA, M., CRUCETA, A., DE LAZZARI, E., GATELL, J.M., AND NEVIRAPINE, EFAVIRENZ, AND ABACAVIR (NEFA) STUDY TEAM. (2003). Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N. Engl. J. Med. 349, 1036-1046.
52. MCCALLISTER, S., KOHLBRENNER, V., SQUIRES, K., LAZZARIN, A., KUMAR, P., DEJESUS, E., NADLER, J., GALLANT, J., WALMSEY, S., YENI, P., LEITH, J., DOHNANYI, C., HALL, D., SABO, J., MACGREGOR, T., VERBIEST, W., MCKENNA, P., AND MAYERS, D. (2003). Characterization of the impact of genotype, phenotype, and inhibitory quotient on antiviral activity of tipranavir in highly treatment-experienced patients. In Programme and Abstracts of the XII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Los Cabos, Mexico, June 10-14. Abstract 12.
53. MELLORS, J., PALMER, S., NISSLEY, D., KEARNEY, M., HALVAS, E., BIXBY, C., DEMETER, L., ESHLEMAN, S., BENNETT, K., HART, S., VAIDA, F., WANTMAN, M., COFFIN, J., HAMMER, S., AND THE ACTG 398 STUDY GROUP. (2004). Low-frequency NNRTI-resistant Variants Contribute to Failure of Efavirenz-containing Regimens. In Programme and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11. Abstract 39.
54. MEYER, P.R., MATSUURA, S.E., SO, A.G., AND SCOTT, W.A. (1998). Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 95, 13471-13476.
55. MILLER, M.D., N. MARGOT, B. LU, L. ZHONG, S. S. CHEN, A. CHENG, AND M. WULFSOHN. (2004). Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral- experienced patients. J. Infect. Dis., 189, 837-846.
56. MONTANER, J., CHUNG, J., GUIMARAES, D., DEMASI, R., GAFOOR, Z., AND SALGO, M. (2004). A treatment staging proposal derived from a post-hoc analysis of the 48 week results from the TORO studies. In Programme and Abstracts of the The XV International AIDS Conference, Bangkok, Thailand, July 11-16. Abstract TuPeB4483.
57. MOYLE, G.J., DEJESUS, E., CAHN, P., CASTILLO, S.A., ZHAO, H., GORDON, D.N., CRAIG, C., SCOTT, T.R. AND ZIAGEN ONCE-DAILY IN ANTIRETROVIRAL COMBINATION THERAPY (CNA30021) STUDY TEAM. (2005). Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J. Acquir. Immune Defic. Syndr., 38, 417-425.
58. NOLAN, D., HAMMOND, E., MARTIN, A., TAYLOR, L., HERRMANN, S., MCKINNON, E., METCALF, C., LATHAM, B., AND MALLAL, S. (2003). Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS, 17, 1329-1338.
59. PATICK, A.K., DURAN, M., CAO, Y., SHUGARTS, D., KELLER, M.R., MAZABEL, E., KNOWLES, M., CHAPMAN, S., KURITZKES, D.R., AND MARKOWITZ, M. (1998). Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother., 42, 2637-2644.
60. PHILLIPS, A.N., DUNN, D., SABIN, C., POZNIAK, A., MATTHIAS, R., GERETTI, A.M., CLARKE, J., CHURCHILL, D., WILLIAMS, I., HILL, T., GREEN, H., PORTER, K., SCULLARD, G., JOHNSON, M., EASTERBROOK, P., GILSON, R., FISHER, M., LOVEDAY, C., GAZZARD, B., PILLAY, D., UK COLLABORATIVE GROUP ON HIV DRUG RESISTANCE., AND UK CHIC STUDY GROUP. (2005). Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS, 19, 487-494.
61. PICARD, V., ANGELINI, E., MAILLARD, A., RACE, E., CLAVEL, F., CHENE, G., FERCHAL, F., AND MOLINA, J.M. (2001). Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J. Infect. Dis. 184, 781-784.
62. POWDERLY, W.G., SAAG, M.S. CHAPMAN, S., YU, G., QUART, B., AND CLENDENINN, N.J. (1999). Predictors of optimal virological response to potent antiretroviral therapy. AIDS, 13, 1873-1880.
63. PUJARI, S.N., DRAVID, A., NAIK, E., BHAGAT, S., TASH, K., NADLER, J.P. AND SINNOTT, J.T. (2005). Lipodystrophy and dyslipidemia among patients taking first-line, world health organization-recommended highly active antiretroviral therapy regimens in Western India. J. Acquir. Immune Defic. Syndr., 39, 199-202.
64. RABOUD, J.M., MONTANER, J.S., CONWAY, B., RAE, S., REISS, P., VELLA, S., COOPER, D., LANGE, J., HARRIS, M., WAINBERG, M.A., ROBINSON, P., MYERS, M., AND HALL, D. (1998). Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS, 12, 1619-1624.
65. ROBBINS, G.K., DE GRUTTOLA, V., SHAFER, R.M., SMEATON, L.M., SNYDER, S.W., PETTINELLI, C., DUBE, M.P., FISCHL, M.A., POLLARD, R.B., DELAPENHA, R., GEDEON, L., VAN DER HORST, C., MURPHY, R.L, BECKER, M.I., D'AQUILA, R.T., VELLA, S., MERIGAN, T.C., HIRSCH, M.S., AND AIDS CLINICAL TRIALS GROUP 384 TEAM. (2003). Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med., 349, 2293-2303.
66. RODRIGUEZ-FRENCH, A., BOGHOSSIAN, J., GRAY, G.E., NADLER, J.P., QUINONES, A.R., SEPULVEDA, G.E. MILLARD, J.M., AND WANNAMAKER, P.G. (2004). The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr., 35, 22-32.
67. SAAG, M.S., CAHN, P., RAFFI, F., WOLFF, M., PEARCE, D., MOLINA, J.M., POWDERLY, W., SHAW, A.L., MONDOU, E., HINKLE, J., BORROTO-ESODA, K., QUINN, J.B., BARRY, D.W., F. ROUSSEAU, F., AND FTC-301A STUDY TEAM. (2004). Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA, 292, 180-189.
68. SHAFER, R.W. (2002). Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev., 15, 247-277.
69. SHULMAN, N.S., MACHEKANO, R.A., SHAFER, R.W., WINTERS, M.A., ZOLOPA, A.R., LIOU, S.H., HUGHES, M., KATZENSTEIN, D.A., AND AIDS CLINICAL TRIALS GROUP 302 STUDY TEAM. (2001). Genotypic correlates of a virologie response to stavudine after zidovudine monotherapy. J. Acquir. Immune Defic. Syndr., 27, 377-380.
70. SHULMAN, N.S., BOSCH, R.J., MELLORS, J.W., ALBRECHT, M.A., AND KATZENSTEIN, D.A. (2004). Genetic correlates of efavirenz hypersusceptibility. AIDS, 18, 1781-1785.
71. SQUIRES, K., LAZZARIN, A., GATELL, J.M., POWDERLY, W.G., POKROVSKIY, V., DELFRAISSY, J.F., J. JEMSEK, RIVERO, A., ROZENBAUM, W., SCHRADER, S., SENSION, M., VIBHAGOOL, A., THIRY, A., AND GIORDANO, M. (2004). Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV. J. Acquir. Immune Defic. Syndr., 36, 1011-1019.
72. STASZEWSKI, S., MORALES-RAMIREZ, J., TASHIMA, K.T., RACHLIS, A., SKIEST, D., STANFORD, J., STRYKER, R., JOHNSON, P., LABRIOLA, D.F., FARINA, D., D.J., AND RUIZ, N.M. (1999). Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med., 341, 1865-1873.
73. TOZZI, V., ZACCARELLI, M., NARCISO, P., TROTTA, M.P., CECCHERINI-SILBERSTEIN, F., DE LONGIS, P., D'OFFIZI, G., FORBICI, F., D'ARRIGO, R., BOUMIS, E., BELLAGAMBA, R., BONFIGLI, S., CARVELLI, C., ANTINORI, A., AND PERNO, C.F. (2004). Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J. Infect. Dis., 189, 1688-1695.
74. VAN DER VALK, M., GISOLF, E.H., REISS, P., WIT, F.W., JAPOUR, A., WEVERLING, G.J., DANNER, S.A., AND PROMETHEUS STUDY GROUP. (2001). Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS, 15, 847-855.
75. VAN LETH, F., PHANUPHAK, P., RUXRUNGTHAM, K., BARALDI, E., MILLER, S., GAZZARD, B., CAHN, P., LALLOO, U.G., VAN DER WESTHUIZEN, I.P., MALAN, D.R., JOHNSON, M.A., SANTOS, B.R., MULCAHY, F., WOOD, R., LEVI, G.C., REBOREDO, G., SQUIRES, K., CASSETTI, I., PETIT, D., RAFFI, F., KATLAMA, C., MURPHY, R.L., HORBAN, A., DAM, J.P., HASSINK, E., VAN LEEUWEN, R., ROBINSON, P., WIT, F.W., LANGE, J.M. AND 2NN STUDY TEAM. (2004). Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet, 363, 1253-1263.
76. WAINBERG, M.A. AND TURNER, D. (2004). Resistance issues with new nucleoside/nucleotide backbone options. J. Acquir. Immune Defic. Syndr., 37, Suppl 1, S36-43.
77. WALKER, U.A., SETZER, B., AND VENHOFF, N. (2002). Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS, 16, 2165-2173.
78. WALMSLEY, S., BERNSTEIN, B., KING, M., ARRIBAS, J., BEALL, G., RUANE, P., JOHNSON, M., JOHNSON, D., LALONDE, R., JAPOUR, A., BRUN, S., SUN, E., AND M98-863 STUDY TEAM. (2002). Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346, 2039-2046.
79. WEBER, J., CHAKRABORTY, B., WEBEROVA, J., MILLER, M.D., AND QUINONES-MATEU, M.E. (2005). Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J. Clin. Microbiol., 43, 1395-1400.
80. WENSING, A.M., VAN DE VIJVER, D.A., ANGARANO, G., ASJO, B., BALOTTA, C., BOERI, E., CAMACHO, R., CHAIX, M.L., COSTAGLIOLA, D., DE LUCA, A., DERDELINCKX, I., GROSSMAN, Z., HAMOUDA, O., HATZAKIS, A., HEMMER, R., HOEPELMAN, A., HORBAN, A., KORN, K., KUCHERER, C., LEITNER, T., LOVEDAY, C., MACRAE, E., MALJKOVIC, I., DE MENDOZA, C., MEYER, L., NIELSEN, C., OP DE COUL, E., ORMAASEN, V., PARASKEVIS, D., PERRIN, L., PUCHHAMMER-STOCKL, E., RUIZ, L., SALMINEN, M., SCHMIT, J.C., SCHNEIDER, F., SCHUURMAN, R., SORIANO, V., STANCZAK, G., STANOJEVIC, M., VANDAMME, A.M., VAN LAETHEM, K., VIOLIN, M., WILBE, K., YERLY, S., ZAZZI, M., BOUCHER, C.A., AND SPREAD PROGRAMME. (2005). Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. J. Infect. Dis., 192, 958-966.
81. WHITCOMB, J.M., HUANG, W., LIMOLI, K., PAXINOS, E., WRIN, T., SKOWRON, G., DEEKS, S.G., BATES, M., HELLMANN, N.S. AND PETROPOULOS, C.J. (2002). Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS, 16, F41-7.
82. WHITCOMB, J.M., PARKIN, N.T., CHAPPEY, C., HELLMANN, N.S., AND PETROPOULOS, C.J. (2003). Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J. Infect. Dis., 188, 992-1000.
83. WHITE, K.L., MARGOT, N.A., WRIN, T., PETROPOULOS, C.J., MILLER, M.D., AND NAEGER, L.K. (2002). Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother., 46, 3437-3446.
84. WINTERS, M.A., BOSCH, R.J., ALBRECHT, M.A., KATZENSTEIN, D.A., AND AIDS CLINICAL TRIALS GROUP 364 STUDY TEAM. (2003). Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients. J. Infect. Dis., 188, 537-540.
85. WOOD, E.,B. YIP, HOGG, R.S. SHERLOCK, C.H., JAHNKE, N., HARRIGAN, R.P.,. O'SHAUGHNESSY, M.V., AND MONTANER, J.S. (2000). Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS, 14, 1955-1960.
86. YOUNG, J., RICKENBACH, M., WEBER, R., FURRER, H., BERNASCONI, E., HIRSCHEL, B., TARR, P.E., VERNAZZA, P., BATTEGAY, M., AND BUCHER, H.C. (2005). Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antivir Ther., 10, 73-81.
87. ZACCARELLI, M., TOZZI, V., LORENZINI, P., TROTTA, M.P., FORBICI, F., VISCO-COMANDINI, U., GORI, C., NARCISO P., PERNO, C,F., ANTINORI, A., AND COLLABORATIVE GROUP FOR CLINICAL USE OF HIV GENOTYPE RESISTANCE TEST (GRT) AT NATIONAL INSTITUTE FOR INFECTIOUS DISEASES LAZZARO SPALLANZANI. (2005). Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS, 19, 1081-1089.